Showcasing Impactful Implementation of Personalised Medicine Approaches
The number of successful implementations of personalised medicine approaches in healthcare is increasing. However, there is a strong need to facilitate the uptake of further personalised medicine approaches while ensuring a sustainable and effective health system.
To support personalised medicine implementation, the European Partnership for Personalised Medicine (EP PerMed) will not only support personalised medicine research, but also continuously map and communicate on progress and achievements within all personalised medicine related areas. These Advances and Learnings in Personalised Medicine include not only innovations and successful implementation in the clinic or even standard care, but can also be supporting (political) frameworks, successful international or interdisciplinary collaboration or citizen engagement or dissemination campaigns.
By sharing these Advances and Learnings and Best Practice Examples, EP PerMed aims to demonstrate the value of personalised medicine in terms of quality of care, quality of life, cost-effectiveness, and sustainability – hoping to motivate others to implement similar approaches.
Background colours:
- blue for research
- yellow for innovation
- green for implementation
- purple for other topics and patient & citizen engagement
Idiographic Monitoring of Vertigo Triggers in Severe Hypoacusis
Category: Advances and Learnings in Personalised Medicine
EP PerMed presents a new “Advance and Learning in Personalised Medicine (APM)” developed at the Aragon Health Sciences Institute (IACS). The project applies personalised medicine by combining passive activity data captured via smartphones with patient reported symptom logging to identify each individual’s vertigo and tinnitus thresholds. The approach captures self-limited vertigo episodes that are typically not recorded in healthcare information systems. The objective is to develop a predictive tool that translates individual patterns into practical, personalised activity guidance, enabling patients to anticipate crises rather than simply react to them.
Genetics-based Personalised Breast Cancer Prevention and Screening
Category: Best Practice in Personalised Medicine
EP PerMed awardes the title of “Best Practice” (BP) in Personalised Medicine to the ‘Genetics-based Personalised Breast Cancer Prevention and Screening’ project as an example of successful implementation of a personalised risk-based breast cancer prevention into real healthcare services. Currently utilised in the private healthcare sectors of several European countries, the service will be implemented in Estonia in 2026 as a national polygenic risk score (PRS)-based personalised breast cancer screening programme for all women aged 40 and over. This programme will use a digital solution integrated into the Estonian e-Health infrastructure.
ESR1 Testing via Liquid Biopsy in Metastatic Breast Cancer
Category: Best Practice in Personalised Medicine
EP PerMed awards the title of “Best Practice” (BP) in Personalised Medicine to Cancer Patients Europe (CPE) and Italian patient associations through the development of a White Paper on ESR1 mutations and the use of liquid biopsy in metastatic breast cancer. This effort stands as an excellent example of how patient advocacy can inform and accelerate implementation of personalised medicine tools, support Health Technology Assessment processes, and ultimately improve outcomes for patients.
Childhood Cancer in Sweden
Category: Best Practice in Personalised Medicine
EP PerMed awards the title of “Best Practice” (BP) in Personalised Medicine to Genomic Medicine Sweden (GMS) for their national implementation of whole-genome and -transcriptome sequencing in childhood cancer in Sweden (GMS Childhood Cancer). GMS Childhood Cancer is dedicated to ensuring that every child diagnosed with cancer in Sweden has access to the most accurate and personalised diagnostics and treatments available.
National Paediatric Screening of Familial Hypercholesterolemia in Luxembourg
Category: Best Practice in Personalised Medicine
EP PerMed awardes the title of “Best Practice” (BP) in Personalised Medicine to the national paediatric screening programme of familial hypercholesterolemia in Luxembourg as an example of successful implementation of a personalised prevention. The programme was launched in November 2025 and is part of a broader European initiative aimed at improving early detection and management of familial hypercholesterolemia through systematic paediatric screening.
French National PRecISion Medicine Center in Oncology (IHU PRISM)
Category: Best Practice in Personalised Medicine
EP PerMed awardes the title of “Best Practice” (BP) in Personalised Medicine to the Institut Hospitalo Universitaire PRISM, National PRecISion Medicine Center in Oncology (PRISM) in France. IHU PRISM is a large, multidisciplinary national institute, dedicated to the advancement and implementation of precision oncology across various types of cancer. Its structure integrates clinical trials, molecular profiling, data science, and experimental biology, specifically designed for a comprehensive patient centric approach.
Regional Healthcare Information Platform in Halland, Sweden
Category: Best Practice in Personalised Medicine
EP PerMed has recently awarded the title of “Best Practice” (BP) in Personalised Medicine to the Regional Healthcare Information Platform in Halland, Sweden. As an integrated healthcare system, Region Halland has committed to fact-based provision, development and research supported by the wealth of data continuously generated in digitalised healthcare. For more than a decade, Region Halland has built information driven care where data science expertise has been added to traditional healthcare competences.
Romania’s Pioneering Law: Establishing the Right to Personalised Medicine
Category: Best Practice in Personalised Medicine
This best practice example discusses Romania’s groundbreaking law, the first in the world to recognise the right of citizens and patients to personalised medicine. Initiated following the EU Council’s 2015 personalised medicine policy, the law is the result of a multi-sectoral collaboration led by the Centre for Innovation in Medicine in Romania, using a quadruple helix model (later developed into a penta helix) involving the academia, public, private and civil society sectors. The law, promulgated on 24 May 2023, gives patients a legal right to personalised health care in a manner that takes into account individual genetic and phenotypic characteristics.
Submit your advances and learnings in personalised medicine as a best practice example here: